首页 > 最新文献

Reumatologia Clinica最新文献

英文 中文
Escorbuto. Una pseudovasculitis olvidada 坏血病。一种被忽视的假性血管炎
IF 1.5 Q4 RHEUMATOLOGY Pub Date : 2024-05-01 DOI: 10.1016/j.reuma.2024.01.001
Noelia Cabaleiro-Raña , Diego Santos-Álvarez , Lucía Romar de las Heras , Carmen Álvarez-Reguera , Evelin Cecilia Cervantes Pérez , Rosa María Hernández Cancela , Susana Romero-Yuste

Scurvy is a nutritional disease caused by ascorbic acid (vitamin C) deficiency. Althought currently it is a rare disease, we should considerer it in the differential diagnosis of purpura and arthritis in patients with restrictive diets.

We present the case of a 49-year-old man with a history of a nutritional disorder presented to our hospital with generalized purpura and hemarthros. Following the anamnesis and laboratory findings, rheumatological, infectious and hematological etiologies were excluded. Finally, the diagnosis of scurvy was made upon demostration poor levels of vitamin C and a spectacular response to nutritional supplements. We compare this case with 19 similar cases reported in the medical literature.

坏血病是一种由抗坏血酸(维生素 C)缺乏引起的营养性疾病。尽管坏血病目前是一种罕见疾病,但我们仍应将其纳入限制饮食患者紫癜和关节炎的鉴别诊断中。本病例中,一名 49 岁的男性患者因全身紫癜和关节炎来我院就诊,既往有营养失调病史。根据病史和实验室检查结果,排除了风湿病、感染性疾病和血液病等病因。最后,根据维生素 C 含量低和对营养补充剂的明显反应,确诊为坏血病。我们将该病例与医学文献中报道的 19 例类似病例进行了比较。
{"title":"Escorbuto. Una pseudovasculitis olvidada","authors":"Noelia Cabaleiro-Raña ,&nbsp;Diego Santos-Álvarez ,&nbsp;Lucía Romar de las Heras ,&nbsp;Carmen Álvarez-Reguera ,&nbsp;Evelin Cecilia Cervantes Pérez ,&nbsp;Rosa María Hernández Cancela ,&nbsp;Susana Romero-Yuste","doi":"10.1016/j.reuma.2024.01.001","DOIUrl":"10.1016/j.reuma.2024.01.001","url":null,"abstract":"<div><p>Scurvy is a nutritional disease caused by ascorbic acid (vitamin C) deficiency. Althought currently it is a rare disease, we should considerer it in the differential diagnosis of purpura and arthritis in patients with restrictive diets.</p><p>We present the case of a 49-year-old man with a history of a nutritional disorder presented to our hospital with generalized purpura and hemarthros. Following the anamnesis and laboratory findings, rheumatological, infectious and hematological etiologies were excluded. Finally, the diagnosis of scurvy was made upon demostration poor levels of vitamin C and a spectacular response to nutritional supplements. We compare this case with 19 similar cases reported in the medical literature.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 5","pages":"Pages 281-285"},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140466168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pósteres: P300-P399 海报:P300-P399
IF 1.5 Q4 RHEUMATOLOGY Pub Date : 2024-05-01 DOI: 10.1016/S1699-258X(24)00064-0
{"title":"Pósteres: P300-P399","authors":"","doi":"10.1016/S1699-258X(24)00064-0","DOIUrl":"https://doi.org/10.1016/S1699-258X(24)00064-0","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 ","pages":"Pages S397-S489"},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141094896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trabajos aceptados solo para publicación 只接受发表的论文
IF 1.5 Q4 RHEUMATOLOGY Pub Date : 2024-05-01 DOI: 10.1016/S1699-258X(24)00060-3
{"title":"Trabajos aceptados solo para publicación","authors":"","doi":"10.1016/S1699-258X(24)00060-3","DOIUrl":"https://doi.org/10.1016/S1699-258X(24)00060-3","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 ","pages":"Pages S55-S130"},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141094892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiopulmonary phenotype in systemic sclerosis associated pulmonary hypertension 系统性硬化症伴肺动脉高压的心肺表型
IF 1.5 Q4 RHEUMATOLOGY Pub Date : 2024-05-01 DOI: 10.1016/j.reuma.2024.01.004
Luis Javier Cajas Santana , Alejandro Correa Giraldo , Maria Carolina Torres

Introduction

Pulmonary hypertension (PH) associated with systemic sclerosis (SSc) increases morbidity and mortality. Cardiopulmonary comorbidities, as per the 2021 PH consensus, play a role in the choice of therapy between monotherapy and combination therapy.

Methods

A cross-sectional study was conducted in patients with SSc based on the 2013 ACR/EULAR criteria or very early disease (VEDOSS 2011). PH was considered if they met the following criteria: pulmonary artery systolic pressure (PASP) > 39 mmHg or peak tricuspid regurgitation velocity (PTRV) > 3.4 m/s, PASP between 33 and 39 mmHg or PTRV between 2.9 and 3.4 m/s plus two additional findings suggestive of PH. PH was classified as type 2 if LVEF < 50% or moderate to severe diastolic dysfunction was present; type 3 if extensive interstitial disease on tomography > 20% or forced vital capacity (FVC) < 75%; type 4 if abnormalities related to embolism were detected on scintigraphy or tomography. If patients did not meet these criteria, they were classified as type 1 PH. Complete data on cardiopulmonary risk factors and other factors were required. The frequency of these factors in the population and differences between groups based on risk factors were estimated.

Results

A total of 228 patients were selected. Three had type 2 PH, 24 had type 3, and 40 had type 1 PH, with the majority (75%) having at least one cardiopulmonary risk factor, and 47.5% having more than one. Mild diastolic dysfunction (25%) and hypertension (35%) were the most prevalent. In the type 1 PH group, those with risk factors experienced an increase in the number of years with Raynaud's phenomenon, anticentromere antibodies, and gastrointestinal symptoms (p < 0.05).

Conclusion

In patients with PH, 75% have one, and 45% have two or more risk factors.

导言与系统性硬化症(SSc)相关的肺动脉高压(PH)会增加发病率和死亡率。根据 2021 PH 共识,心肺合并症在选择单药治疗还是联合治疗时起着重要作用。方法根据 2013 年 ACR/EULAR 标准或极早期疾病(2011 年 VEDOSS)对 SSc 患者进行横断面研究。如果患者符合以下标准,则考虑为PH:肺动脉收缩压(PASP)大于39 mmHg或三尖瓣反流峰值速度(PTRV)大于3.4 m/s,PASP介于33和39 mmHg之间或PTRV介于2.9和3.4 m/s之间,再加上两个提示PH的其他结果。如果存在 LVEF < 50% 或中度至重度舒张功能障碍,则 PH 被归为 2 型;如果断层扫描显示广泛的间质病变 >20%,或用力肺活量 (FVC) < 75%,则 PH 被归为 3 型;如果在闪烁扫描或断层扫描中发现与栓塞有关的异常,则 PH 被归为 4 型。如果患者不符合这些标准,则被归类为 1 型 PH。需要提供有关心肺危险因素和其他因素的完整数据。结果 共有 228 名患者入选。其中 3 人属于 2 型 PH,24 人属于 3 型 PH,40 人属于 1 型 PH,大多数人(75%)至少有一个心肺危险因素,47.5% 的人有一个以上的危险因素。轻度舒张功能障碍(25%)和高血压(35%)最为普遍。在 1 型 PH 组中,有危险因素的患者出现雷诺现象、抗中心粒抗体和胃肠道症状的年数增加(p < 0.05)。
{"title":"Cardiopulmonary phenotype in systemic sclerosis associated pulmonary hypertension","authors":"Luis Javier Cajas Santana ,&nbsp;Alejandro Correa Giraldo ,&nbsp;Maria Carolina Torres","doi":"10.1016/j.reuma.2024.01.004","DOIUrl":"10.1016/j.reuma.2024.01.004","url":null,"abstract":"<div><h3>Introduction</h3><p>Pulmonary hypertension (PH) associated with systemic sclerosis (SSc) increases morbidity and mortality. Cardiopulmonary comorbidities, as per the 2021 PH consensus, play a role in the choice of therapy between monotherapy and combination therapy.</p></div><div><h3>Methods</h3><p>A cross-sectional study was conducted in patients with SSc based on the 2013 ACR/EULAR criteria or very early disease (VEDOSS 2011). PH was considered if they met the following criteria: pulmonary artery systolic pressure (PASP)<!--> <!-->&gt;<!--> <!-->39<!--> <!-->mmHg or peak tricuspid regurgitation velocity (PTRV)<!--> <!-->&gt;<!--> <!-->3.4<!--> <!-->m/s, PASP between 33 and 39<!--> <!-->mmHg or PTRV between 2.9 and 3.4<!--> <!-->m/s plus two additional findings suggestive of PH. PH was classified as type 2 if LVEF<!--> <!-->&lt;<!--> <!-->50% or moderate to severe diastolic dysfunction was present; type 3 if extensive interstitial disease on tomography<!--> <!-->&gt;<!--> <!-->20% or forced vital capacity (FVC)<!--> <!-->&lt;<!--> <!-->75%; type 4 if abnormalities related to embolism were detected on scintigraphy or tomography. If patients did not meet these criteria, they were classified as type 1 PH. Complete data on cardiopulmonary risk factors and other factors were required. The frequency of these factors in the population and differences between groups based on risk factors were estimated.</p></div><div><h3>Results</h3><p>A total of 228 patients were selected. Three had type 2 PH, 24 had type 3, and 40 had type 1 PH, with the majority (75%) having at least one cardiopulmonary risk factor, and 47.5% having more than one. Mild diastolic dysfunction (25%) and hypertension (35%) were the most prevalent. In the type 1 PH group, those with risk factors experienced an increase in the number of years with Raynaud's phenomenon, anticentromere antibodies, and gastrointestinal symptoms (<em>p</em> <!-->&lt;<!--> <!-->0.05).</p></div><div><h3>Conclusion</h3><p>In patients with PH, 75% have one, and 45% have two or more risk factors.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 5","pages":"Pages 243-248"},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140089151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Consenso Delphi sobre el uso de la telemedicina en reumatología: estudio RESULTAR 关于在风湿病学中使用远程医疗的德尔菲共识:RESULTAR 研究
IF 1.5 Q4 RHEUMATOLOGY Pub Date : 2024-05-01 DOI: 10.1016/j.reuma.2024.01.005
Jenaro Graña Gil , María José Moreno Martínez , María del Carmen Carrasco Cubero

Background and objectives

There is growing interest in the potential of telemedicine (TM) as an alternative to physical consultation. Although numerous studies prove the benefits of TM in rheumatology, there are no recommendations on its implementation in Spain. The aim of this study was to analyze the application of TM in rheumatology consultations in Spain.

Materials and methods

Qualitative, cross-sectional, multicenter study with Delphi methodology in 2 rounds of queries. A structured ad hoc questionnaire was designed that included statements on teleconsultation, nursing teleconsultation, telecare, telerehabilitation, teleradiology, telehealth tele-education, main barriers, advantages and disadvantages of telehealth tele-education and TM in rheumatoid arthritis. The participants were rheumatology specialists practicing in Spain.

Results

The participating rheumatologists (N = 80) had a mean age of 42.4 (± 9.0) years, with 12.6 (± 8.4) years of experience. Some of the aspects of TM that obtained the greatest consensus were: TM is useful for follow-up of some patients, to help determine if a face-to-face consultation is necessary, or to assist patients with rheumatoid arthritis if they present low activity or in remission; certain patients, such as those in their first consultation or those who present digital barriers or cognitive deterioration, should be seen face-to-face; TM presents some technical and patient access barriers; TM can be useful in nursing and in continued medical education.

Conclusions

TM can be beneficial for the treatment and follow-up of patients with rheumatic diseases, as well as for alleviating the face-to-face care burden in rheumatology.

背景和目的远程医疗(TM)作为物理会诊的一种替代方式,其潜力正受到越来越多的关注。尽管大量研究证明了远程医疗在风湿病学中的益处,但在西班牙却没有实施远程医疗的建议。本研究旨在分析远程医疗在西班牙风湿病学会诊中的应用情况。材料和方法采用德尔菲法进行两轮询问的定性、横断面、多中心研究。设计了一份结构化的特别问卷,其中包括远程会诊、护理远程会诊、远程护理、远程康复、远程放射学、远程医疗远程教育、远程医疗远程教育的主要障碍、优缺点以及类风湿关节炎中的远程医疗。结果参与研究的风湿病专家(N = 80)平均年龄为 42.4(± 9.0)岁,拥有 12.6(± 8.4)年的工作经验。就 TM 的一些方面达成的最大共识是TM 对于一些患者的随访非常有用,有助于确定是否有必要进行面对面会诊,或者在类风湿性关节炎患者活动较少或病情缓解时为其提供帮助;某些患者,如初诊患者或存在数字障碍或认知能力衰退的患者,应进行面对面会诊;TM 在技术和患者使用方面存在一些障碍;TM 在护理和继续医学教育方面非常有用。结论 TM 有利于风湿病患者的治疗和随访,也有利于减轻风湿病学中面对面护理的负担。
{"title":"Consenso Delphi sobre el uso de la telemedicina en reumatología: estudio RESULTAR","authors":"Jenaro Graña Gil ,&nbsp;María José Moreno Martínez ,&nbsp;María del Carmen Carrasco Cubero","doi":"10.1016/j.reuma.2024.01.005","DOIUrl":"10.1016/j.reuma.2024.01.005","url":null,"abstract":"<div><h3>Background and objectives</h3><p>There is growing interest in the potential of telemedicine (TM) as an alternative to physical consultation. Although numerous studies prove the benefits of TM in rheumatology, there are no recommendations on its implementation in Spain. The aim of this study was to analyze the application of TM in rheumatology consultations in Spain.</p></div><div><h3>Materials and methods</h3><p>Qualitative, cross-sectional, multicenter study with Delphi methodology in 2 rounds of queries. A structured ad hoc questionnaire was designed that included statements on teleconsultation, nursing teleconsultation, telecare, telerehabilitation, teleradiology, telehealth tele-education, main barriers, advantages and disadvantages of telehealth tele-education and TM in rheumatoid arthritis. The participants were rheumatology specialists practicing in Spain.</p></div><div><h3>Results</h3><p>The participating rheumatologists (N<!--> <!-->=<!--> <!-->80) had a mean age of 42.4 (±<!--> <!-->9.0) years, with 12.6 (±<!--> <!-->8.4) years of experience. Some of the aspects of TM that obtained the greatest consensus were: TM is useful for follow-up of some patients, to help determine if a face-to-face consultation is necessary, or to assist patients with rheumatoid arthritis if they present low activity or in remission; certain patients, such as those in their first consultation or those who present digital barriers or cognitive deterioration, should be seen face-to-face; TM presents some technical and patient access barriers; TM can be useful in nursing and in continued medical education.</p></div><div><h3>Conclusions</h3><p>TM can be beneficial for the treatment and follow-up of patients with rheumatic diseases, as well as for alleviating the face-to-face care burden in rheumatology.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 5","pages":"Pages 254-262"},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140462375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Infecciones graves en vasculitis necrosantes sistémicas 全身坏死性血管炎的严重感染
IF 1.5 Q4 RHEUMATOLOGY Pub Date : 2024-05-01 DOI: 10.1016/j.reuma.2024.01.003
Claudia Pena, Ana Carolina Costi, Lucila García, Mercedes García

Infections in patients with systemic vasculitis represent one of the main causes of mortality. Corticosteroid use, immunosuppressive therapy, age, associated organic involvement and dialysis dependence are risk factors of infection.

Objectives

To determine the prevalence of severe infection and associated factors in patients diagnosed with ANCA-associated vasculitis and polyarteritis nodosa (PAN).

Methods

Retrospective study was conduced in a single rheumatology center (2000-2018). We included patients diagnosed with ANCA-associated vasculitis (granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis and PAN. Serious infectious events requiring hospitalization or prolonged antibiotic/antiviral treatment, recurrent infection of herpes zoster virus or opportunistic infections were evaluated. Sites of infection, isolated microorganisms and mortality related were analyzed.

Results

A total of 105 patients were analyzed, follow-up time median 18 months, 58.7% were women and median age was 52 years. Types of vasculitis: 41.9% microscopic polyangiitis, 16.2% eosinophilic granulomatosis with polyangiitis, 40% granulomatosis with polyangiitis, 1.9% PAN. Constitutional, pulmonary, renal and otorhinolaryngology manifestations were the most frequent.

The prevalence of infection

was 34,2%, with a median of 3 months from diagnosis of vasculitis to the infectious event. Low respiratory tract (42.8%), sepsis (31.4%), and urinary tract (14.3%) were the most common sites of infections. Bacterial etiology was the most prevalent (67.7%). Mortality at the first event was 14.3% and a 72.2% of patients were in the induction phase of treatment.

Infectious events were significantly associated with age > 65 years (P = 0.030), presence of lung (P = 0.016) and renal involvement (P = 0.001), BVASv3 > 15 and mortality (P = 0.0002).

Conclusions

The prevalence of infection was 34.2%. Lower airway infections, septicemia and urinary tract infections were the most prevalent. Infections were associated with renal and pulmonary involvement, age older than 65 years and score BVAS >15. Severe infections were associated with mortality, especially in elderly patients.

全身性血管炎患者感染是导致死亡的主要原因之一。方法 在一个风湿病学中心开展了一项回顾性研究(2000-2018 年)。我们纳入了被诊断为ANCA相关性血管炎(肉芽肿伴多血管炎、嗜酸性肉芽肿伴多血管炎、显微镜下多血管炎和结节性多动脉炎)的患者。对需要住院治疗或长期抗生素/抗病毒治疗的严重感染事件、带状疱疹病毒反复感染或机会性感染进行了评估。结果 共分析了 105 名患者,随访时间中位数为 18 个月,58.7% 为女性,年龄中位数为 52 岁。血管炎类型:41.9%为显微镜下多血管炎,16.2%为嗜酸性粒细胞肉芽肿伴多血管炎,40%为肉芽肿伴多血管炎,1.9%为PAN。感染率为 34.2%,从确诊血管炎到发生感染事件的中位时间为 3 个月。低呼吸道(42.8%)、败血症(31.4%)和泌尿道(14.3%)是最常见的感染部位。细菌是最常见的病因(67.7%)。感染事件与年龄(65 岁)(P = 0.030)、肺部(P = 0.016)和肾脏受累(P = 0.001)、BVASv3(15)和死亡率(P = 0.0002)显著相关。下呼吸道感染、脓毒血症和尿路感染最为常见。感染与肾脏和肺部受累、65 岁以上和 BVAS 评分 15 分有关。严重感染与死亡率有关,尤其是在老年患者中。
{"title":"Infecciones graves en vasculitis necrosantes sistémicas","authors":"Claudia Pena,&nbsp;Ana Carolina Costi,&nbsp;Lucila García,&nbsp;Mercedes García","doi":"10.1016/j.reuma.2024.01.003","DOIUrl":"10.1016/j.reuma.2024.01.003","url":null,"abstract":"<div><p>Infections in patients with systemic vasculitis represent one of the main causes of mortality. Corticosteroid use, immunosuppressive therapy, age, associated organic involvement and dialysis dependence are risk factors of infection.</p></div><div><h3>Objectives</h3><p>To determine the prevalence of severe infection and associated factors in patients diagnosed with ANCA-associated vasculitis and polyarteritis nodosa (PAN).</p></div><div><h3>Methods</h3><p>Retrospective study was conduced in a single rheumatology center (2000-2018). We included patients diagnosed with ANCA-associated vasculitis (granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis and microscopic polyangiitis and PAN. Serious infectious events requiring hospitalization or prolonged antibiotic/antiviral treatment, recurrent infection of herpes zoster virus or opportunistic infections were evaluated. Sites of infection, isolated microorganisms and mortality related were analyzed.</p></div><div><h3>Results</h3><p>A total of 105 patients were analyzed, follow-up time median 18 months, 58.7% were women and median age was 52 years. Types of vasculitis: 41.9% microscopic polyangiitis, 16.2% eosinophilic granulomatosis with polyangiitis, 40% granulomatosis with polyangiitis, 1.9% PAN. Constitutional, pulmonary, renal and otorhinolaryngology manifestations were the most frequent.</p></div><div><h3>The prevalence of infection</h3><p>was 34,2%, with a median of 3 months from diagnosis of vasculitis to the infectious event. Low respiratory tract (42.8%), sepsis (31.4%), and urinary tract (14.3%) were the most common sites of infections. Bacterial etiology was the most prevalent (67.7%). Mortality at the first event was 14.3% and a 72.2% of patients were in the induction phase of treatment.</p><p>Infectious events were significantly associated with age<!--> <!-->&gt; 65 years (<em>P</em> <!-->=<!--> <!-->0.030), presence of lung (<em>P</em> <!-->=<!--> <!-->0.016) and renal involvement (<em>P</em> <!-->=<!--> <!-->0.001), BVASv3<!--> <!-->&gt; 15 and mortality (<em>P</em> <!-->=<!--> <!-->0.0002).</p></div><div><h3>Conclusions</h3><p>The prevalence of infection was 34.2%. Lower airway infections, septicemia and urinary tract infections were the most prevalent. Infections were associated with renal and pulmonary involvement, age older than 65 years and score BVAS<!--> <!-->&gt;15. Severe infections were associated with mortality, especially in elderly patients.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 5","pages":"Pages 237-242"},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140469368","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of polypharmacy and drug interaction in older adults with rheumatic disease 患有风湿病的老年人多药治疗和药物相互作用的普遍性
IF 1.5 Q4 RHEUMATOLOGY Pub Date : 2024-05-01 DOI: 10.1016/j.reuma.2024.02.006
Rodrigo Lozano-Lozano , David Vega-Morales , Macarena del Rosario Sifuentes-Martinez , Denisse Ornelas-Balcazar

Introduction/Aim

Older people with rheumatic diseases tend to have a greater number of associated comorbidities, which will require the use of more drugs, increasing the risk of hospitalizations, complications, and drug interactions. In Mexico, there has been an estimated prevalence of polypharmacy of up to 55%, however there are scarce reports on the topic in our elderly population with rheumatic diseases. We aimed to determine the prevalence of polypharmacy and the association of drug interactions in patients treated for rheumatic disease.

Methods

A retrospective observational study was conducted on patients undergoing treatment for rheumatic diseases who were treated in geriatrics and rheumatology clinics from January to December 2021. The presence of polypharmacy and drug interactions was evaluated using the BOT Plus Pharmacological Surveillance System. The prevalence of polypharmacy and the association of drug interactions were estimated.

Results

We evaluated 320 patients, with a mean age of 67.05 ± 5.8 years, predominantly female (85%). The prevalence of polypharmacy was 68.1% (n = 218), of which 214 (98.1%) patients had related drug interactions; 27.1% were severe and 53.2% as moderate interactions. Factors related with increased risk of drug interactions were being exposed to hypertension increased the risk of drug interactions (POR 1.75, 95% CI 1.44–2.14; P < 0.001), having osteoarthritis (POR 1.21, 95% CI 1.04–1.42; P = 0.032) and thyroid disease (POR 1.45, 95% CI 1.28–1.65; P = 0.001). The most prevalent serious interactions were leflunomide–methotrexate in 27 (46.5%) patients and buprenorphine–tramadol in 8 (13.7%).

Conclusions

A high prevalence of polypharmacy and drug interactions was observed in elderly patients with rheumatic diseases. The main associated factors were comorbidities, particularly high blood pressure, osteoarthritis and thyroid diseases.

导言/目的患有风湿病的老年人往往合并有更多的相关疾病,需要使用更多的药物,从而增加了住院、并发症和药物相互作用的风险。据估计,墨西哥的多药滥用率高达 55%,但有关我国风湿病老年人群多药滥用的报道却很少。我们旨在确定接受风湿病治疗的患者中多重用药的发生率以及药物相互作用的相关性。方法:我们对 2021 年 1 月至 12 月期间在老年病学和风湿病学诊所接受治疗的风湿病患者进行了一项回顾性观察研究。研究使用 BOT Plus 药物监测系统对多药治疗和药物相互作用进行了评估。结果我们评估了 320 名患者,平均年龄为 67.05 ± 5.8 岁,主要为女性(85%)。使用多种药物的比例为 68.1%(n = 218),其中 214 例(98.1%)患者存在相关药物相互作用;27.1% 为严重相互作用,53.2% 为中度相互作用。与药物相互作用风险增加有关的因素包括:高血压会增加药物相互作用的风险(POR 1.75,95% CI 1.44-2.14;P <;0.001)、骨关节炎(POR 1.21,95% CI 1.04-1.42;P = 0.032)和甲状腺疾病(POR 1.45,95% CI 1.28-1.65;P = 0.001)。最常见的严重相互作用是来氟米特-甲氨蝶呤(27 例,占 46.5%)和丁丙诺啡-曲马多(8 例,占 13.7%)。主要相关因素是合并症,尤其是高血压、骨关节炎和甲状腺疾病。
{"title":"Prevalence of polypharmacy and drug interaction in older adults with rheumatic disease","authors":"Rodrigo Lozano-Lozano ,&nbsp;David Vega-Morales ,&nbsp;Macarena del Rosario Sifuentes-Martinez ,&nbsp;Denisse Ornelas-Balcazar","doi":"10.1016/j.reuma.2024.02.006","DOIUrl":"10.1016/j.reuma.2024.02.006","url":null,"abstract":"<div><h3>Introduction/Aim</h3><p>Older people with rheumatic diseases tend to have a greater number of associated comorbidities, which will require the use of more drugs, increasing the risk of hospitalizations, complications, and drug interactions. In Mexico, there has been an estimated prevalence of polypharmacy of up to 55%, however there are scarce reports on the topic in our elderly population with rheumatic diseases. We aimed to determine the prevalence of polypharmacy and the association of drug interactions in patients treated for rheumatic disease.</p></div><div><h3>Methods</h3><p>A retrospective observational study was conducted on patients undergoing treatment for rheumatic diseases who were treated in geriatrics and rheumatology clinics from January to December 2021. The presence of polypharmacy and drug interactions was evaluated using the BOT Plus Pharmacological Surveillance System. The prevalence of polypharmacy and the association of drug interactions were estimated.</p></div><div><h3>Results</h3><p>We evaluated 320 patients, with a mean age of 67.05<!--> <!-->±<!--> <!-->5.8 years, predominantly female (85%). The prevalence of polypharmacy was 68.1% (<em>n</em> <!-->=<!--> <!-->218), of which 214 (98.1%) patients had related drug interactions; 27.1% were severe and 53.2% as moderate interactions. Factors related with increased risk of drug interactions were being exposed to hypertension increased the risk of drug interactions (POR 1.75, 95% CI 1.44–2.14; <em>P</em> <!-->&lt;<!--> <!-->0.001), having osteoarthritis (POR 1.21, 95% CI 1.04–1.42; <em>P</em> <!-->=<!--> <!-->0.032) and thyroid disease (POR 1.45, 95% CI 1.28–1.65; <em>P</em> <!-->=<!--> <!-->0.001). The most prevalent serious interactions were leflunomide–methotrexate in 27 (46.5%) patients and buprenorphine–tramadol in 8 (13.7%).</p></div><div><h3>Conclusions</h3><p>A high prevalence of polypharmacy and drug interactions was observed in elderly patients with rheumatic diseases. The main associated factors were comorbidities, particularly high blood pressure, osteoarthritis and thyroid diseases.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 5","pages":"Pages 249-253"},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140760215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiovascular disease in patients with systemic autoimmune diseases: The relationship between self-perceived risk and actual risk 系统性自身免疫疾病患者的心血管疾病:自我感觉风险与实际风险之间的关系
IF 1.5 Q4 RHEUMATOLOGY Pub Date : 2024-05-01 DOI: 10.1016/j.reuma.2024.01.002
Cristiana Sieiro Santos , Maria Miguel Oliveira , Paulo Ney Solari , Pedro Mateus , Maria José Santos , Hector Corominas , Carolina Álvarez Castro , Elvira Díez Álvarez

Introduction

Autoimmune diseases are known to be associated with an elevated risk of cardiovascular diseases; however, there exists a lack of awareness regarding this increased risk among patients.

Objective

This study aimed to assess the prevalence of cardiovascular risk factors and events in various systemic autoimmune diseases, including Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Sjögren's syndrome (SS), matched by age, sex, and disease duration. Additionally, the study aimed to evaluate the perceived and actual risks of cardiovascular disease among patients.

Methods

A cross-sectional self-reported survey on the patient's perspective of cardiovascular risk was conducted between January and June 2023. Sociodemographic and clinical data, including disease activity, were collected through medical records and questionnaires. Traditional cardiovascular risk factors and events were assessed, alongside the perceived cardiovascular risk. The SCORE calculation and Charlson Comorbidity Index (CCI) were employed for cardiovascular risk assessment.

Results

Survey responses from 180 patients (45 patients each with SSc, SLE, RA, and SS) with systemic autoimmune diseases revealed that 20% perceived a low risk, 23% perceived neither lower nor higher, and 56% perceived a higher risk of developing cardiovascular diseases in the next ten years. Only 45% agreed that their autoimmune disease could increase the risk of a heart attack, even in the absence of other risk factors, and 46.7% were unaware that NSAIDs pose a cardiovascular risk. An association between cardiovascular risk measured by SCORE, comorbidities, and risk perception was observed in RA, SSc, and SS patients, with no association found in SLE patients (p = 0.27). Except for SS patients (p = 0.02), no association between CCI and disease activity level was found. Regarding the influence of age, working status, and education in CVD risk perception, an association between CVD risk perception and age was observed (p = 0.01), with patients over 40 years exhibiting a higher perception of CVD risk. No differences were found regarding working status (p = 0.19) nor education level (p = 0.06).

Conclusions

Patients with SS, RA, and SSc displayed a heightened perception of cardiovascular risk, correlating with their actual risk and preexisting comorbidities. However, patients exhibited unawareness of certain cardiovascular risk behaviors. This underscores the need for tailored education programs on cardiovascular risk for autoimmune disease patients, to be implemented at the time of diagnosis and during follow-up in outpatient clinics.

导言:众所周知,自身免疫性疾病与心血管疾病风险升高有关;然而,患者对这种风险升高缺乏认识。本研究旨在评估各种系统性自身免疫性疾病(包括系统性硬化症(SSc)、系统性红斑狼疮(SLE)、类风湿性关节炎(RA)和斯约格伦综合征(SS))中心血管风险因素和事件的发生率,并根据年龄、性别和病程进行匹配。此外,该研究还旨在评估患者感知到的和实际存在的心血管疾病风险。方法在 2023 年 1 月至 6 月期间进行了一项横断面自我报告调查,内容涉及患者对心血管疾病风险的看法。通过病历和问卷收集了社会人口学和临床数据,包括疾病活动性。在评估心血管风险的同时,还评估了传统的心血管风险因素和事件。结果对 180 名系统性自身免疫疾病患者(系统性红斑狼疮、系统性红斑狼疮、RA 和 SS 患者各 45 名)进行的调查显示,20% 的患者认为未来 10 年罹患心血管疾病的风险较低,23% 的患者认为风险既不低也不高,56% 的患者认为风险较高。只有 45% 的人同意,即使没有其他风险因素,他们的自身免疫性疾病也会增加心脏病发作的风险,46.7% 的人不知道非甾体抗炎药会带来心血管风险。在 RA、SSc 和 SS 患者中,通过 SCORE 测量的心血管风险、合并症和风险认知之间存在关联,而在系统性红斑狼疮患者中未发现关联(p = 0.27)。除 SS 患者(p = 0.02)外,CCI 与疾病活动程度之间没有关联。关于年龄、工作状况和教育程度对心血管疾病风险认知的影响,观察到心血管疾病风险认知与年龄之间存在关联(p = 0.01),40 岁以上的患者对心血管疾病风险的认知度更高。结论 SS、RA 和 SSc 患者对心血管风险的认知度较高,这与他们的实际风险和既往合并症相关。然而,患者对某些心血管风险行为并不了解。这强调了为自身免疫性疾病患者量身定制心血管风险教育计划的必要性,该计划应在诊断时和门诊随访期间实施。
{"title":"Cardiovascular disease in patients with systemic autoimmune diseases: The relationship between self-perceived risk and actual risk","authors":"Cristiana Sieiro Santos ,&nbsp;Maria Miguel Oliveira ,&nbsp;Paulo Ney Solari ,&nbsp;Pedro Mateus ,&nbsp;Maria José Santos ,&nbsp;Hector Corominas ,&nbsp;Carolina Álvarez Castro ,&nbsp;Elvira Díez Álvarez","doi":"10.1016/j.reuma.2024.01.002","DOIUrl":"10.1016/j.reuma.2024.01.002","url":null,"abstract":"<div><h3>Introduction</h3><p>Autoimmune diseases are known to be associated with an elevated risk of cardiovascular diseases; however, there exists a lack of awareness regarding this increased risk among patients.</p></div><div><h3>Objective</h3><p>This study aimed to assess the prevalence of cardiovascular risk factors and events in various systemic autoimmune diseases, including Systemic Sclerosis (SSc), Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), and Sjögren's syndrome (SS), matched by age, sex, and disease duration. Additionally, the study aimed to evaluate the perceived and actual risks of cardiovascular disease among patients.</p></div><div><h3>Methods</h3><p>A cross-sectional self-reported survey on the patient's perspective of cardiovascular risk was conducted between January and June 2023. Sociodemographic and clinical data, including disease activity, were collected through medical records and questionnaires. Traditional cardiovascular risk factors and events were assessed, alongside the perceived cardiovascular risk. The SCORE calculation and Charlson Comorbidity Index (CCI) were employed for cardiovascular risk assessment.</p></div><div><h3>Results</h3><p>Survey responses from 180 patients (45 patients each with SSc, SLE, RA, and SS) with systemic autoimmune diseases revealed that 20% perceived a low risk, 23% perceived neither lower nor higher, and 56% perceived a higher risk of developing cardiovascular diseases in the next ten years. Only 45% agreed that their autoimmune disease could increase the risk of a heart attack, even in the absence of other risk factors, and 46.7% were unaware that NSAIDs pose a cardiovascular risk. An association between cardiovascular risk measured by SCORE, comorbidities, and risk perception was observed in RA, SSc, and SS patients, with no association found in SLE patients (<em>p</em> <!-->=<!--> <!-->0.27). Except for SS patients (<em>p</em> <!-->=<!--> <!-->0.02), no association between CCI and disease activity level was found. Regarding the influence of age, working status, and education in CVD risk perception, an association between CVD risk perception and age was observed (<em>p</em> <!-->=<!--> <!-->0.01), with patients over 40 years exhibiting a higher perception of CVD risk. No differences were found regarding working status (<em>p</em> <!-->=<!--> <!-->0.19) nor education level (<em>p</em> <!-->=<!--> <!-->0.06).</p></div><div><h3>Conclusions</h3><p>Patients with SS, RA, and SSc displayed a heightened perception of cardiovascular risk, correlating with their actual risk and preexisting comorbidities. However, patients exhibited unawareness of certain cardiovascular risk behaviors. This underscores the need for tailored education programs on cardiovascular risk for autoimmune disease patients, to be implemented at the time of diagnosis and during follow-up in outpatient clinics.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 5","pages":"Pages 229-236"},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140763732","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From clots to cuts in antiphospholipid syndrome 抗磷脂综合征从血凝块到切口
IF 1.5 Q4 RHEUMATOLOGY Pub Date : 2024-05-01 DOI: 10.1016/j.reuma.2023.10.005
Abihai Lucas Hernández , Yehuda Shoenfeld
{"title":"From clots to cuts in antiphospholipid syndrome","authors":"Abihai Lucas Hernández ,&nbsp;Yehuda Shoenfeld","doi":"10.1016/j.reuma.2023.10.005","DOIUrl":"https://doi.org/10.1016/j.reuma.2023.10.005","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 5","pages":"Page 286"},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140824105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comunicaciones orales 口头交流
IF 1.5 Q4 RHEUMATOLOGY Pub Date : 2024-05-01 DOI: 10.1016/S1699-258X(24)00059-7
{"title":"Comunicaciones orales","authors":"","doi":"10.1016/S1699-258X(24)00059-7","DOIUrl":"https://doi.org/10.1016/S1699-258X(24)00059-7","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":"20 ","pages":"Pages S1-S54"},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141094891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Reumatologia Clinica
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1